Dr. Mark A. Ranalli, MD
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
At a glance
- In the NPI registry since
- 2005
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
OH license 35076785 -
Pediatrics Physician
OH license 35076785
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $25,605 in research payments for these studies, mostly to the institutions running them.
- B19-061 Ph 3 Pediatric Study of venetoclax and chemotherapy
AbbVie Inc. - Phase 1 study to evaluate the safety and pharmacokinetics of palbociclib ibranceregistered in combination with irinotecan and temozolomide and in combination with topotecan and cyclophosphamide in pediatric patients w…
Pfizer Inc. - Phase 12 study to evaluate palbociclib ibrance in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent or refractory solid tumors
Pfizer Inc. - ANBL1531 lorlatinib arm a phase 3 study of 131IMETAIODOBENZYLGUANIDINE 131IMIBG or alk inhibitor therapy added to intensive therapy for children with newly diagnosed highrisk neuroblastoma nbl
Pfizer Inc. - A single arm phase II trial in first line high risk HR pediatric and young adult patients with Bcell acute lymphoblastic leukemia ALL who are minimal residual disease MRD positive at end of consolidation EOC therapy
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.